ADMA Biologics Inc (NASDAQ:ADMA) Short Interest Update

ADMA Biologics Inc (NASDAQ:ADMA) was the recipient of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 25,826,838 shares, a growth of 35.0% from the February 26th total of 19,137,458 shares. Approximately 11.3% of the shares of the stock are sold short. Based on an average daily volume of 3,625,752 shares, the short-interest ratio is currently 7.1 days.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ADMA shares. Zacks Research upgraded ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $32.00.

ADMA Biologics Stock Up 11.6%

ADMA opened at $9.25 on Friday. The firm has a 50-day simple moving average of $15.60 and a two-hundred day simple moving average of $16.42. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $25.67. The company has a market capitalization of $2.20 billion, a PE ratio of 15.42 and a beta of 0.51. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.20. The firm had revenue of $139.16 million for the quarter, compared to analysts’ expectations of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business’s revenue was up 18.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.46 earnings per share. Analysts forecast that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

More ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Company issues formal refutation of Culper Research’s allegations, calling the report “unsubstantiated, misleading and inaccurate” and defending ASCENIV’s competitive position and revenue recognition. ADMA refutes short-seller claims
• Positive Sentiment: Market coverage notes a rebound after the company’s rebuttal — headlines and articles report ADMA “gains” as traders react to management’s statements. ADMA gains after refuting claims
• Positive Sentiment: Analysts and media flag market attention including Nasdaq reactions and commentary that the company is actively addressing investor concerns — helpful for short‑term sentiment. Market attention coverage
• Neutral Sentiment: Unusual options activity was reported (large call buying), suggesting speculative positioning that can amplify intraday moves but not fundamental direction. (Options volume reported in market notices.)
• Neutral Sentiment: Context pieces note ADMA is down significantly since its last earnings release, highlighting volatility tied to recent results and expectations — useful for evaluating risk vs. reward. Zacks: stock down since earnings
• Negative Sentiment: Multiple securities‑fraud investigations and investor alerts have been launched by a number of law firms after the short report and the subsequent price decline — this increases legal risk and could pressure the stock. Investor investigations announced
• Negative Sentiment: Short‑seller allegations (including claims of channel stuffing) remain in circulation via reports and investor alerts; third‑party scrutiny prompted steep intraday declines last week and remains a key downside risk. Investor alert on short‑seller report
• Negative Sentiment: Cantor Fitzgerald moved the stock after the short‑report fallout (coverage/ratings action reported), adding analyst pressure on sentiment. Cantor Fitzgerald downgrade

Insiders Place Their Bets

In other news, Director Steve Elms bought 7,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were bought at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the purchase, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. This represents a 2.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.50% of the stock is currently owned by insiders.

Institutional Trading of ADMA Biologics

Hedge funds have recently modified their holdings of the company. Summit Securities Group LLC bought a new position in shares of ADMA Biologics during the 4th quarter valued at approximately $29,000. Salomon & Ludwin LLC bought a new stake in ADMA Biologics in the third quarter worth $25,000. Rothschild Investment LLC increased its position in ADMA Biologics by 373.8% in the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares during the last quarter. Optima Capital LLC purchased a new stake in ADMA Biologics during the fourth quarter valued at $36,000. Finally, Clearstead Advisors LLC raised its stake in ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 795 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.